Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin a Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest Inc executives and other stock owners filed with the SEC include: